However, it is essential to note that sustained elevation in plasma glucose concentrations due to reduced pancreatic insulin release from chronic melatonin treatment, especially when extending beyond the sleeping period [140], may compromise melatonin’s potential to ameliorate AD pathology [141, 142]. Here, INS is linked to Alzheimer disease.